Detail

Basic Information Clinical Results Relationship Graph

Gene symbol	LPA	Synonyms	AK38, APOA, LP	Type of gene	protein-coding
Chromosome	6	Map location	6q25.3-q26	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas
Description	lipoprotein(a)

GTO ID	GTC0518
Trial ID	NCT04270760
Disease	Cardiovascular System Disease
Altered gene	LPA
Therapeutic/Target gene	Target gene
Therapy	siRNA
Treatment	Olpasiran\|AMG 890
Phase	Phase2
Recruitment status	Completed
Title	A Double-blind, Randomized, Placebo-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Olpasiran (AMG 890) in Subjects With Elevated Lipoprotein(a)
Year	2020
Country	Australia\|Canada\|Denmark\|Iceland\|Japan\|Netherlands\|United States
Company sponsor	Amgen
Other ID(s)	20180109\|2019-003688-23

Cohort1: olpasiran_dose level 1

Administration route	subcutaneous injection
Dosage	olpasiran, 10 mg, Q12W for 48 weeks
Pts	58
Age	Adult, Older_Adult
Outcome	Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36:-66.91
Adverse reactions	0/58(All-cause mortality); 3/58(Cardiac disorders; Infections and infestations; Injury, poisoning and procedural complications; Product Issues)
References	PMID: 36342163

Cohort2: olpasiran_dose level 2

Administration route	subcutaneous injection
Dosage	olpasiran, 75 mg, Q12W for 48 weeks
Pts	58
Age	Adult, Older_Adult
Outcome	Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36:-93.78
Adverse reactions	0/58(All-cause mortality); 3/58(Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Renal and urinary disorders)
References	PMID: 36342163

Cohort3: olpasiran_dose level 3

Administration route	subcutaneous injection
Dosage	olpasiran, 225 mg, Q12W for 48 weeks
Pts	56
Age	Adult, Older_Adult
Outcome	Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36:-97.53
Adverse reactions	0/56(All-cause mortality); 6/56(Cardiac disorders; astrointestinal disorders; General disorders; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Vascular disorders)
References	PMID: 36342163

Cohort4: olpasiran_dose level 4

Administration route	subcutaneous injection
Dosage	olpasiran, 225 mg, Q24W for 48 weeks
Pts	55
Age	Adult, Older_Adult
Outcome	Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36:-96.89
Adverse reactions	0/55(All-cause mortality); 4/55(Cardiac disorders; General disorders; Infections and infestations; Nervous system disorders; Skin and subcutaneous tissue disorders)
References	PMID: 36342163

Cohort5: Placebo

Administration route	subcutaneous injection
Dosage	Placebo, Q12W for 48 weeks
Pts	54
Age	Adult, Older_Adult
Outcome	Percentage Change From Baseline in Lipoprotein(a) (Lp[a]) at Week 36:3.60
Adverse reactions	1/54(All-cause mortality); 8/54(Cardiac disorders; General disorders; Infections and infestations; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Vascular disorders)
References	PMID: 36342163

Cohort6: Extended Safety Follow Cohort1

Administration route	subcutaneous injection
Pts	57
Age	Adult, Older_Adult
Adverse reactions	0/57(All-cause mortality); 4/57(Cardiac disorders; Eye disorders; Gastrointestinal disorders; Nervous system disorders)
References	PMID: 36342163

Cohort7: Extended Safety Follow Cohort2

Administration route	subcutaneous injection
Pts	57
Age	Adult, Older_Adult
Adverse reactions	0/57(All-cause mortality); 2/57(Infections and infestations; Injury, poisoning and procedural complications)
References	PMID: 36342163

Cohort8: Extended Safety Follow Cohort3

Administration route	subcutaneous injection
Pts	54
Age	Adult, Older_Adult
Adverse reactions	0/54(All-cause mortality); 6/54(Gastrointestinal disorders; Infections and infestations; Musculoskeletal and connective tissue disorders; Psychiatric disorders; Vascular disorders)
References	PMID: 36342163

Cohort9: Extended Safety Follow Cohort4

Administration route	subcutaneous injection
Pts	55
Age	Adult, Older_Adult
Adverse reactions	0/55(All-cause mortality); 5/55(Cardiac disorders; Gastrointestinal disorders; Infections and infestations)
References	PMID: 36342163

Cohort10: Extended Safety Follow Cohort5

Administration route	subcutaneous injection
Pts	53
Age	Adult, Older_Adult
Adverse reactions	0/53(All-cause mortality); 4/53(Hepatobiliary disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders)
References	PMID: 36342163

Overview of Knowledge Graph